NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Core Insights - NervGen Pharma's NVG-291-R shows significant functional recovery in preclinical models for traumatic hearing loss and peripheral nerve injury, indicating broad therapeutic potential [1][2][8] Preclinical Study Findings - NVG-291-R demonstrated significant hearing restoration in rat models exposed to blast-induced sensorineural hearing loss, with improvements in hearing thresholds across all frequencies by Day 30 [4][6] - In models of peripheral nerve injury, NVG-291-R treatment led to significant improvements in neuromuscular function and axonal regeneration, with observable gains as early as 4 weeks post-injury [7][6] Broader Implications - The findings reinforce NVG-291's potential as a first-in-class neuroreparative therapeutic, with applications in both military and civilian populations suffering from nerve damage [8][9] - The studies presented at the 2025 Military Health System Research Symposium highlight the ability of NVG-291 to promote nervous system repair across various injury models [8][9] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics, with NVG-291 being its lead candidate currently undergoing clinical trials [10]